- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05548127
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
TACTIVE-U: An Interventional Safety and Efficacy Phase 1b/2, Open-label Umbrella Study to Investigate Tolerability, pk, and Antitumor Activity of Vepdegestrant (ARV-471/PF-07850327), an Oral Proteolysis Targeting Chimera, in Combination With Other Anticancer Treatments in Participants Aged 18 Years and Over With ER+ Advanced or Metastatic Breast Cancer, Sub-study A (ARV-471 in Combination With Abemaciclib)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
This study is seeking participants who have breast cancer that:
- is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy
- is sensitive to hormonal therapy (it is called estrogen receptor positive); and
- is no longer responding to previous treatments This study is divided into separate sub-studies.
For Sub-Study A:
All participants will receive ARV-471 and a medicine called abemaciclib. ARV-471 will be given by mouth, at home, 1 time a day. Abemaciclib will be given by mouth, at home, 2 times a day. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and effective.
Participants will continue to take ARV-471 and abemaciclib until their cancer is no longer responding, or side effects become too severe. They will have visits at the study clinic about every 4 weeks.
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Pfizer CT.gov Call Center
- Phone Number: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Recruiting
- BC Cancer Vancouver
-
Vancouver, British Columbia, Canada, V5Z 1H7
- Recruiting
- BC Cancer Vancouver
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Recruiting
- The Ottawa Hospital - General Campus
-
Toronto, Ontario, Canada, M4N 3M5
- Recruiting
- Sunnybrook Research Institute
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 5H6
- Recruiting
- CIUSSS- saguenay-Lac-Saint-Jean
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital
-
-
-
-
-
Ancona, Italy, 60126
- Not yet recruiting
- Azienda Ospedaliero Universitaria delle Marche
-
Padova, Italy, 35128
- Not yet recruiting
- Istituto Oncologico Veneto IRCCS
-
-
Campania
-
Napoli, Campania, Italy, 80131
- Not yet recruiting
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
-
-
Catania
-
Misterbianco, Catania, Italy, 95045
- Not yet recruiting
- Humanitas Istituto Clinico Catanese
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Not yet recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
-
-
Lombardia
-
Monza, Lombardia, Italy, 20900
- Not yet recruiting
- Fondazione IRCCS San Gerardo dei Tintori
-
-
Torino
-
Candiolo, Torino, Italy, 10060
- Not yet recruiting
- Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
-
-
-
-
-
Madrid, Spain, 28007
- Recruiting
- Hospital General Universitario Gregorio Marañón
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Universitario Virgen del Rocío
-
-
Barcelona [barcelona]
-
Barcelona, Barcelona [barcelona], Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
-
Catalunya [cataluña]
-
Barcelona, Catalunya [cataluña], Spain, 08028
- Recruiting
- Hospital Universitari Dexeus
-
-
Madrid, Comunidad DE
-
Madrid, Madrid, Comunidad DE, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Madrid, Comunidad DE, Spain, 28027
- Recruiting
- Clinica Universidad de Navarra
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra
-
-
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- Stanford Women's Cancer Center
-
Palo Alto, California, United States, 94304
- Not yet recruiting
- Stanford Women's Cancer Center
-
San Francisco, California, United States, 94158
- Recruiting
- UCSF Medical Center at Mission Bay
-
-
Florida
-
Tampa, Florida, United States, 33612
- Not yet recruiting
- Moffitt Cancer Center
-
Tampa, Florida, United States, 33612
- Not yet recruiting
- Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center
-
Tampa, Florida, United States, 33607
- Not yet recruiting
- Moffitt Cancer Center - International Plaza
-
-
Illinois
-
Shiloh, Illinois, United States, 62269
- Recruiting
- Siteman Cancer Center - WUPI
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Not yet recruiting
- Brigham and Women's Hospital
-
Newton, Massachusetts, United States, 02459
- Not yet recruiting
- Dana-Farber Cancer Institute - Chestnut Hill
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Recruiting
- Siteman Cancer Center - West County
-
Florissant, Missouri, United States, 63031
- Recruiting
- Siteman Cancer Center - North County
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Barnes-Jewish Hospital
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University
-
Saint Louis, Missouri, United States, 63129
- Recruiting
- Siteman Cancer Center - South County
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine - Siteman Cancer Center
-
Saint Peters, Missouri, United States, 63376
- Recruiting
- Siteman Cancer Center - St Peters
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Recruiting
- U.T. MD Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Recruiting
- U.T. MD Anderson Cancer Center, Investigational Pharmacy Services - Unit 376
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- histological or cytological diagnosis of ER+ and HER2- advanced/metastatic breast cancer that is not amendable to surgical resection with curative intent (≥1% ER+ stained cells on the most recent tumor biopsy).
- prior anticancer therapies: at least 1 and no more than 2 lines of prior therapies for advanced/metastatic disease; 1 line of any CDK4/6 inhibitor-based regimen is required (independent of the setting eg, adjuvant or advanced/metastatic)
- at least 1 measurable lesion as defined by RECIST v1.1.
- ECOG PS ≤1.
Exclusion Criteria:
- visceral crisis at risk of life-threatening complications in the short term
- known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung functions.
- newly diagnosed brain metastases, or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. Participants with a history of CNS metastases or cord compression are eligible if they have been definitively treated, clinically stable and discontinued anti-seizure medications and corticosteroids for at least 14 days prior to enrollment in the study.
- history of any other tumor malignancies within the past 3 years, except for the following: (1) adequately treated basal or squamous cell carcinoma of the skin; (2) curatively treated in situ carcinoma of the cervix.
- inflammatory breast cancer
- impaired cardiovascular function or clinically significant cardiovascular diseases
- concurrent administration of medications, food, or herb supplements that are strong inhibitors and strong/moderate inducers of CYP3A and drugs known to predispose to Torsade de Pointes or QT interval prolongation.
- renal impairment, not adequate liver function and/or bone marrow function
- known active infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARV-471 in combination with Abemaciclib
ARV-471 administered orally once daily (QD) and Abemaciclib orally twice daily (BID) on 28-day cycle
|
Daily oral dosages of ARV-471 continuously, dose escalation/de-escalation in Phase 1b until the recommended phase 2 dose (RP2D) determined, cycles lasting 28 days
Other Names:
Daily oral dosages of Abemaciclib continuously, cycles lasting 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: number of participants with dose limiting toxicities
Time Frame: 28 days
|
Dose Limiting Toxicities rate for ARV-471 in combination with abemaciclib, estimated based on data from DLT-evaluable participants during the DLT observation period (Cycle 1 [28 days]).
|
28 days
|
Phase 2: percentage of participants with objective response by investigator assessment
Time Frame: Up to approximately 1 year
|
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.
as determined by investigator assessment.
|
Up to approximately 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b and Phase2: Percentage of participants with Clinical Benefit Response by investigator assessment.
Time Frame: Up to approximately 1 year
|
Clinical Benefit Response (CBR) is defined as the proportion of participants with Best Overall Response of confirmed CR or PR at any time, or Stable Disease (SD) ≥24 weeks
|
Up to approximately 1 year
|
Phase 1b and Phase 2: Progression Free Survival by investigator assessment.
Time Frame: Up to approximately 1 year
|
Progression Free Survival (PFS) is defined as the time from the date of first dose of study interventions to the date of first documentation of PD or death due to any cause, whichever occurs first.
|
Up to approximately 1 year
|
Phase 2: Overall Survival
Time Frame: Through study completion, up to approximately 3 year
|
Overall Survival (OS) is defined as the time from the date of first dose of study interventions to the date of death due to any cause
|
Through study completion, up to approximately 3 year
|
Phase 1b and Phase 2: number of participants experiencing any AE, SAE, Treatment Related SAE
Time Frame: Up to 28 days after last dose of study treatment
|
An adverse event (AE) were any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE is any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events. Treatment-related AE is any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were graded by the investigator according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) and coded using MedDRA were reported. Grade 1=mild; Grade 2=moderate; Grade 3=severe and Grade 4=life-threatening or disabling and grade 5=death. |
Up to 28 days after last dose of study treatment
|
Phase 1b and Phase 2: number of participants with lab abnormalities - Hematology and coagulation parameters
Time Frame: Up to 28 days after last dose of study treatment
|
Blood samples were collected for the analysis of following hematology and coagulation parameters: hemoglobin [g/L], platelets, leukocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils [10^9/L]; partial thromboplastin time prolonged, international normalized ratio increased, prothrombin time. Number of participants with hematological and coagulation abnormalities by grade as per CTCAE version 5.0 were reported. Grade 1=mild; Grade 2=moderate; Grade 3=severe and Grade 4=life-threatening or disabling and grade 5=death. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, abnormal, or not done. |
Up to 28 days after last dose of study treatment
|
Phase 1b and Phase 2: number of participants with lab abnormalities - chemistry parameters
Time Frame: Up to 28 days after last dose of study treatment
|
Blood samples were collected for analysis of clinical chemistry parameters. These included: alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, [international unit per liter (IU/L)] ; Lipase and amilase [IU/L] (limited to cycle1 only); Albumin, bilirubin, urea ,calcium, creatinine, glucose, magnesium, phosphate, uric acid, chloride, potassium and sodium [millimol per liter (mmol/L)]; eGFR [milliliter per minute (ml/min)]. Number of participants with blood chemistry abnormalities by grade as per CTCAE version 5.0 were reported. Grade 1=mild; Grade 2=moderate; Grade 3=severe and Grade 4=life-threatening or disabling and grade 5=death. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, abnormal, or not done. |
Up to 28 days after last dose of study treatment
|
Phase 1b: percentage of participants with objective response by investigator assessment
Time Frame: Up to approximately 1 year
|
Objective response (OR) refers to confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.
as determined by investigator assessment.
|
Up to approximately 1 year
|
Phase 1b and Phase 2: duration of response by investigator assessment.
Time Frame: Up to approximately 1 year
|
Duration of Response (DoR) is defined for participants with confirmed OR (CR or PR) as the time from the first documentation of OR to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
|
Up to approximately 1 year
|
Phase 2:ctDNA plasma quantitative changes from pre-treatment
Time Frame: Day 1, 29 and 57 and End of Treatment (an average of 1 year)
|
To assess changes from baseline levels in plasma circulating DNA (ctDNA) with treatment and to evaluate potential predictability of their associations with clinical outcome
|
Day 1, 29 and 57 and End of Treatment (an average of 1 year)
|
Phase 1b: Area Under the Curve from Time Zero to end of dosing interval Evaluation of abemaciclib with or without ARV-471
Time Frame: Phase 1b: pre-dose Day -1, 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 29 and 43
|
Exposure (AUCtau) of abemaciclib with and without co-administration of ARV-471
|
Phase 1b: pre-dose Day -1, 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 29 and 43
|
Phase 1b: Maximum Observed Plasma Concentration (Cmax) of abemaciclib with or without ARV-471
Time Frame: Phase 1b: pre-dose Day -1, 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 29 and 43
|
Concentration (Cmax) of abemaciclib with and without co-administration of ARV-471
|
Phase 1b: pre-dose Day -1, 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 29 and 43
|
Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of ARV-471
Time Frame: Phase 1b: pre-dose Day 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day 15; post dose Day 29 and 43. Phase 2: pre and post dose Day 15, 29 and 43; pre - dose Day 57, 113 and 169
|
Plasma concentration of ARV-471
|
Phase 1b: pre-dose Day 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day 15; post dose Day 29 and 43. Phase 2: pre and post dose Day 15, 29 and 43; pre - dose Day 57, 113 and 169
|
Phase 1b and Phase 2: Maximum Observed Plasma Concentration (Cmax) of abemaciclib
Time Frame: Phase 1b: pre-dose Day -1, 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 29, 43 and 57 Phase 2: pre and post dose Day 15, 29 and 43; pre - dose Day 57, 113 and 169
|
Plasma concentration of abemaciclib
|
Phase 1b: pre-dose Day -1, 1, 15, 29, 43, 57, 113, 169; 1, 2, 4, 6, 8 hours post dose on Day -1 and 15; post dose Day 29, 43 and 57 Phase 2: pre and post dose Day 15, 29 and 43; pre - dose Day 57, 113 and 169
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C4891006
- 2022-502228-34-00 (Registry Identifier: CTIS (EU))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on ARV-471
-
PfizerArvinas Estrogen Receptor, Inc.Completed
-
PfizerArvinas Estrogen Receptor, Inc.Active, not recruiting
-
PfizerArvinas Estrogen Receptor, Inc.Active, not recruiting
-
Arvinas Estrogen Receptor, Inc.PfizerActive, not recruiting
-
PfizerArvinas Estrogen Receptor, Inc.RecruitingBreast CancerUnited States, Canada, Spain, Italy
-
PfizerArvinas Estrogen Receptor, Inc.RecruitingBreast CancerUnited States, Japan, Puerto Rico
-
PfizerArvinas Estrogen Receptor, Inc.; Carrick Therapeutics LimitedRecruitingBreast CancerUnited States, Belgium, Puerto Rico
-
PfizerArvinas Estrogen Receptor, Inc.Completed
-
PfizerArvinas Estrogen Receptor, Inc.RecruitingAdvanced Breast CancerChina, Japan, United States, Taiwan, Canada, Korea, Republic of, Spain, Bulgaria, Turkey, Finland, Italy, Czechia, India, Slovakia, South Africa, Germany, Australia, Brazil, Greece, Puerto Rico, Belgium, Argentina, Switzerland, Poland, ... and more
-
PfizerArvinas Estrogen Receptor, Inc.Recruiting